A 65 year old asymptomatic woman sees you for therapy. She has a positive family history of early CV mortality. Her cholesterol is over 400 with intolerance to statins. She carries a diagnosis of homozygous familial hypercholesterolemia (HoFH). What is the role of the new PCSK9 inhibitors in treating patients like the one described above?
Dr. Heuser is interested to hear what your approach would be with this patient. Please comment below with your thoughts.
We hope to see you at the upcoming Cardiovascular Disease Management symposium, taking place October 1-2, 2015. For the detailed program, registration, CME, and hotel information, please visit: http://promedicacme.com/meeting/Cardiovascular-Disease-Management-A-Case-Based-110.html.